PD-L2
Adult
Apoptosis
/ drug effects
Arginase
/ metabolism
B7-H1 Antigen
/ metabolism
Cell Differentiation
/ drug effects
Cell Proliferation
/ drug effects
Female
Humans
Inflammation
/ metabolism
Interferon-gamma
/ pharmacology
Interleukin-2
/ metabolism
Lectins, C-Type
/ metabolism
Macrophages
/ cytology
Male
Mannose Receptor
Mannose-Binding Lectins
/ metabolism
Middle Aged
Programmed Cell Death 1 Ligand 2 Protein
/ metabolism
Programmed Cell Death 1 Receptor
/ metabolism
Proto-Oncogene Proteins
/ genetics
Reactive Oxygen Species
/ metabolism
Receptor Protein-Tyrosine Kinases
/ genetics
Receptors, Cell Surface
/ metabolism
Th1 Cells
/ drug effects
Tumor Necrosis Factor-alpha
/ metabolism
Wound Healing
/ drug effects
c-Mer Tyrosine Kinase
/ genetics
Axl Receptor Tyrosine Kinase
IFNγ
PD-1
PD-L1
T cell
inflammation
wound healing
Journal
Immunology and cell biology
ISSN: 1440-1711
Titre abrégé: Immunol Cell Biol
Pays: United States
ID NLM: 8706300
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
03
06
2019
revised:
11
12
2019
accepted:
11
12
2019
pubmed:
18
12
2019
medline:
21
10
2020
entrez:
18
12
2019
Statut:
ppublish
Résumé
Depending on the microenvironment conditions, macrophages display phenotypic and functional heterogeneity. This study characterized the programmed cell death-ligand 2 (PD-L2)-expressing macrophage-like cells drained from surgical wound zones, and investigated their influence on helper T (Th) cell responses. Although all CD14
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
IL2 protein, human
0
Interleukin-2
0
Lectins, C-Type
0
Mannose Receptor
0
Mannose-Binding Lectins
0
PDCD1 protein, human
0
PDCD1LG2 protein, human
0
Programmed Cell Death 1 Ligand 2 Protein
0
Programmed Cell Death 1 Receptor
0
Proto-Oncogene Proteins
0
Reactive Oxygen Species
0
Receptors, Cell Surface
0
Tumor Necrosis Factor-alpha
0
Interferon-gamma
82115-62-6
MERTK protein, human
EC 2.7.10.1
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
TYRO3 protein, human
EC 2.7.10.1
c-Mer Tyrosine Kinase
EC 2.7.10.1
ARG1 protein, human
EC 3.5.3.1
Arginase
EC 3.5.3.1
Axl Receptor Tyrosine Kinase
0
AXL protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
152-164Informations de copyright
© 2019 Australian and New Zealand Society for Immunology Inc.
Références
Muraille E, Leo O, Moser M. TH1/TH2 paradigm extended: macrophage polarization as an unappreciated pathogen-driven escape mechanism? Front Immunol 2014; 5: 603.
Ley K. M1 Means kill; M2 means heal. J Immunol 2017; 199: 2191-2193.
Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 2004; 76: 509-513.
Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 2014; 6: 13.
Porcheray F, Viaud S, Rimaniol AC, et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 2005; 142: 481-489.
Das A, Sinha M, Datta S, et al. Monocyte and macrophage plasticity in tissue repair and regeneration. Am J Pathol 2015; 185: 2596-2606.
Gao CH, Dong HL, Tai L, Gao XM. Lactoferrin-containing immunocomplexes drive the conversion of human macrophages from M2- into M1-like phenotype. Front Immunol 2018; 9: 37.
Hirayama D, Iida T, Nakase H. The phagocytic function of macrophage-enforcing innate immunity and tissue homeostasis. Int J Mol Sci 2017; 19: E92.
Magee CN, Boenisch O, Najafian N. The role of costimulatory molecules in directing the functional differentiation of alloreactive T helper cells. Am J Transplant 2012; 12: 2588-2600.
Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 2010; 28: 445-489.
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13: 227-242.
Kursunel MA, Esendagli G. The untold story of IFN-gamma in cancer biology. Cytokine Growth Factor Rev 2016; 31: 73-81.
Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep 2017; 19: 1189-1201.
Ou JN, Wiedeman AE, Stevens AM. TNF-alpha and TGF-beta counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus. Sci Rep 2012; 2: 295.
Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity 2016; 44: 450-462.
Behm B, Babilas P, Landthaler M, Schreml S. Cytokines, chemokines and growth factors in wound healing. J Eur Acad Dermatol Venereol 2012; 26: 812-820.
Evans ND, Oreffo RO, Healy E, Thurner PJ, Man YH. Epithelial mechanobiology, skin wound healing, and the stem cell niche. J Mech Behav Biomed Mater 2013; 28: 397-409.
Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol 2014; 5: 614.
Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327: 656-661.
Kelley JL, Rozek MM, Suenram CA, Schwartz CJ. Activation of human blood monocytes by adherence to tissue culture plastic surfaces. Exp Mol Pathol 1987; 46: 266-278.
Esendagli G, Yoyen-Ermis D, Guseinov E, et al. Impact of repeated abdominal surgery on wound healing and myeloid cell dynamics. J Surg Res 2018; 223: 188-197.
Wilgus TA, Roy S, McDaniel JC. Neutrophils and wound repair: positive actions and negative reactions. Adv Wound Care 2013; 2: 379-388.
He L, Marneros AG. Macrophages are essential for the early wound healing response and the formation of a fibrovascular scar. Am J Pathol 2013; 182: 2407-2417.
Martinez FO, Helming L, Milde R, et al. Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood 2013; 121: e57-e69.
Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA 2003; 100: 5336-5341.
Dolen Y, Esendagli G. Myeloid leukemia cells with a B7-2+ subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands. Eur J Immunol 2013; 43: 747-757.
Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236: 219-242.
Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012; 2012: 656340.
Shapouri-Moghaddam A, Mohammadian S, Vazini H, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol 2018; 233: 6425-6440.
Noppen M, De Waele M, Li R, et al. Volume and cellular content of normal pleural fluid in humans examined by pleural lavage. Am J Respir Crit Care Med 2000; 162: 1023-1026.
Perlman H, Nguyen N, Liu H, et al. Rheumatoid arthritis synovial fluid macrophages express decreased tumor necrosis factor-related apoptosis-inducing ligand R2 and increased decoy receptor tumor necrosis factor-related apoptosis-inducing ligand R3. Arthritis Rheum 2003; 48: 3096-3101.
Myers KV, Amend SR, Pienta KJ. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. Mol Cancer 2019; 18: 94.
Akinrinmade OA, Chetty S, Daramola AK, Islam MU, Thepen T, Barth S. CD64: an attractive immunotherapeutic target for M1-type macrophage mediated chronic inflammatory diseases. Biomedicines 2017; 5: 56.
Gautier EL, Shay T, Miller J, et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol 2012; 13: 1118-1128.
Grabiec AM, Goenka A, Fife ME, Fujimori T, Hussell T. Axl and MerTK receptor tyrosine kinases maintain human macrophage efferocytic capacity in the presence of viral triggers. Eur J Immunol 2018; 48: 855-860.
Salahuddin SZ, Markham PD, Gallo RC. Establishment of long-term monocyte suspension cultures from normal human peripheral blood. J Exp Med 1982; 155: 1842-1857.
Miller PJ, Stevenson HC. Suspension culture of human monocytes. Methods Enzymol 1986; 132: 243-250.
Koh TJ, DiPietro LA. Inflammation and wound healing: the role of the macrophage. Expert Rev Mol Med 2011; 13: e23.
Trombetta AC, Soldano S, Contini P, et al. A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement. Respir Res 2018; 19: 186.
Li W, Katz BP, Spinola SM. Haemophilus ducreyi-induced interleukin-10 promotes a mixed M1 and M2 activation program in human macrophages. Infect Immun 2012; 80: 4426-4434.
Smith TD, Tse MJ, Read EL, Liu WF. Regulation of macrophage polarization and plasticity by complex activation signals. Integr Biol 2016; 8: 946-955.
Billiau A, Matthys P. Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev 2009; 20: 97-113.
Carter L, Fouser LA, Jussif J, et al. PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur J Immunol 2002; 32: 634-643.
Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268.
Nie X, Chen W, Zhu Y, et al. B7-DC (PD-L2) costimulation of CD4+ T-helper 1 response via RGMb. Cell Mol Immunol 2018; 15: 888-897.
Karunarathne DS, Horne-Debets JM, Huang JX, et al. Programmed death-1 ligand 2-mediated regulation of the PD-L1 to PD-1 axis is essential for establishing CD4+ T cell immunity. Immunity 2016; 45: 333-345.
Yamazaki T, Akiba H, Koyanagi A, Azuma M, Yagita H, Okumura K. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol 2005; 175: 1586-1592.
Terrazas LI, Montero D, Terrazas CA, Reyes JL, Rodriguez-Sosa M. Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis. Int J Parasitol 2005; 35: 1349-1358.
Stempin CC, Motran CC, Aoki MP, Falcon CR, Cerban FM, Cervi L. PD-L2 negatively regulates Th1-mediated immunopathology during Fasciola hepatica infection. Oncotarget 2016; 7: 77721-77731.
Huber S, Hoffmann R, Muskens F, Voehringer D. Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2. Blood 2010; 116: 3311-3320.